Pdb74 - Ideglira Versus Iglarlixi for Patients With Inadequately Controlled Type 2 Diabetes on Basal Insulin: A Long-Term Cost-Effectiveness Analysis in the Czech Republic

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.779
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

An Indirect Treatment Comparison of the Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine/Lixisenatide (iGlarLixi) in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin

Journal of Medical Economics
Health Policy
2017English

Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin or Exenatide in Patients With Inadequately Controlled Type 2 Diabetes on Oral Antidiabetic Drugs in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients With Type 2 Diabetes Receiving Basal–Bolus Therapy

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Cost-Effectiveness Analysis of Exenatide Twice Daily (BID) Versus Insulin Glargine Once Daily (QD) as Add-On Therapy in Chinese Patients With Type 2 Diabetes Mellitus Inadequately Controlled by Oral Therapies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Pdb67 - Once-Weekly Semaglutide Versus Dulaglutide for the Treatment of Patients With Type 2 Diabetes in Portugal: A Long-Term Cost-Effectiveness Analysis Based on Sustain 7

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Clinical Benefit of Basal Insulin Analogue Treatment in Persons With Type 2 Diabetes Inadequately Controlled on Prior Insulin Therapy: A Prospective, Noninterventional, Multicenter Study

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

Efficacy and Safety of Three-Times-Daily Versus Twice-Daily Biphasic Insulin Aspart 30 in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Combined With Oral Antidiabetic Drugs

Diabetes Research and Clinical Practice
Internal MedicineEndocrinologyMetabolismMedicineDiabetes
2019English

Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden

Applied Health Economics and Health Policy
MedicineHealth PolicyEconomicsEconometrics
2017English

Pdb64 - Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients With Type 2 Diabetes

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy